Relamorelin to Treat Constipation: “Pusher” or Pushover?

Bassotti, Gabrio

doi:10.1007/s10620-015-3929-9

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 66 These effects have been related to the stimulation of colonic high-amplitude propagated contractions in these patients, 67 even though this effect appears to be weaker compared to other laxatives. 68 , 69 To date, no other studies have been published with this drug in CIC patients.…”

Section: Emerging Treatment Optionsmentioning

confidence: 99%

Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options

Bassotti

Usai-Satta

Bellini

2021

CEG

Self Cite

View full text Add to dashboard Cite

Chronic idiopathic constipation (CIC) is a common functional bowel disorder characterized by difficult, infrequent, and/or incomplete defecation. It has a great impact on the quality of life and on health care system and represents a heavy economic burden. The diagnosis is based on symptoms, classified by the Rome IV criteria. The aim of this review was to evaluate the current therapeutic guidelines for adult CIC and highlight new emerging treatments. In detail, European, French, Spanish and Korean guidelines have been identified and compared. Osmotic laxatives, and in particular polyethylene glycol, represent the first-line therapeutic approach. Stimulant laxatives are recommended as a second-line therapy. Pelvic floor rehabilitation is recommended in patients with ano-rectal dyssynergia. In patients who fail to improve with pharmacological therapies sacral nerve stimulation is considered as last chance before surgery. Surgical approach has however limited indications in selected cases. Inertia coli refractory to any approach and obstructed defecation are two subtypes which can benefit from surgery. Among emerging agents, prucalopride, a prokinetic agent, is recommended as a second-line treatment in refractory CIC patients. In addition, the secretagogues linaclotide and plecanatide and the bile acid transported inhibitor elobixibat can be effective in patients not responsive to a second-line therapeutic regimen, although they are not worldwide commercially available.

show abstract

Section: Emerging Treatment Optionsmentioning

confidence: 99%

Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options

Bassotti

Usai-Satta

Bellini

2021

CEG

Self Cite

View full text Add to dashboard Cite

show abstract

Velusetrag for the treatment of chronic constipation

Bassotti

Gambaccini

Bellini

2016

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

After analyzing the available data, the authors feel that velusetrag may likely improve symptoms and the quality of life of chronically constipated subjects. However, additional data is needed to fully understand the safety and efficacy of velusetrag, particularly in patients on long-term therapy. Thanks to the once-daily dosing and the pharmacologic properties, velusetrag could be used as a single agent or in association with other drugs. In the future, this drug holds the potential to be an effective adjunct to the therapeutic armamentarium for chronic constipation.

show abstract